<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04098432</url>
  </required_header>
  <id_info>
    <org_study_id>CA209- 9KH</org_study_id>
    <nct_id>NCT04098432</nct_id>
  </id_info>
  <brief_title>Stereotactic Radiotherapy + Anti PD-1 Therapy in Patients With Locally Advanced Unresectable Pancreatic Adenocarcinoma</brief_title>
  <acronym>CA209-9KH</acronym>
  <official_title>Stereotactic Radiotherapy + Anti PD-1 Therapy in Patients With Locally Advanced Unresectable Pancreatic Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Hradec Kralove</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>GCP-Service International s.r.o.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Hradec Kralove</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stereotactic Radiotherapy + Anti PD-1 Therapy in Patients With Locally Advanced Unresectable
      Pancreatic Adenocarcinoma
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase I/II, multicentre, open label, with no control arm clinical trial of 4-weeks
      stereotactic radiotherapy followed by nivolumab 3 mg/kg every two weeks in adults with
      locally advanced pancreatic cancer who does not progress during 4 cycles of standard
      chemotherapy FOLFIRINOX
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 3, 2018</start_date>
  <completion_date type="Anticipated">December 3, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 3, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety - incidence of treatment-related adverse events</measure>
    <time_frame>Through study completion, an average of 4 years</time_frame>
    <description>Measured by the incidence of adverse events (AEs), serious adverse events (SAEs), deaths</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety - incidence of laboratory abnormalities</measure>
    <time_frame>Through study completion, an average of 4 years</time_frame>
    <description>Biochemistry - Na (mmol/l), K (mmol/l), Cl (mmol/l), Ca (mmol/l), Ca ionized (mmol/l), Mg (mmol/l), P (mmol/l), urea (mmol/l), creatinine (µmol/l), LDH (µkat/l), AST(µkat/l), ALT(µkat/l), ALP(µkat/l), GMT(µkat/l), total bilirubin (µmol/l), conjuged bilirubin (µmol/l), total protein (g/l), albumin (g/l), fasting glucose (mmol/l), amylase (µkat/l), C-reactive protein (mg/l), endocrine panel - TSH (mU/l), Free T3 (pmol/l), Free T4 (pmol/l), hematology - complete blood count (CBC): hemoglobin (g/l), hematocrit (ratio), white blood cells (WBC) (10E9/l), red blood cells (10E12/l), platelets (10E9/l) including differential (all 10E9/l), coagulation - APTT (ratio), PT (ratio)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Through study completion, an average of 4 years</time_frame>
    <description>To evaluate progression free survival (median of progression free survival and 1-, 2-year progression free survival)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Through study completion, an average of 4 years</time_frame>
    <description>To evaluate overall survival (median of overall survival and 1-, 2-year overall survival)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship of laboratory markers and progression</measure>
    <time_frame>Through study completion, an average of 4 years</time_frame>
    <description>To evaluate the relationship of laboratory markers (PD-L1 expression, tumor infiltrating lymphocytes presence, neopterin level) to progression status and time related progress of biomarkers (CEA, CA19-9)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>patient's capacity to fulfill the activities of daily living and quality of life</measure>
    <time_frame>Through study completion, an average of 4 years</time_frame>
    <description>Assess by questionnaire European Organisation for Research and Treatment of Cancer (EORTC) Quality of life questionnaire (QLQ-C30) questionnaire. The EORTC QLQ-C30 comprises 30 items (i.e. single questions), 24 of which are aggregated into 9 multi-item scales, that is, 5 functioning scales (physical, role, cognitive, emotional and social), 3 symptom scales (fatigue, pain and nausea/vomiting) and one global health status scale. The remaining 6 single-item (dyspnoea, appetite loss, sleep disturbance, constipation, diarrhoea and the financial impact) scales assess symptoms.All of the scales and single-item measures range in score from 0 to 100. Higher score for the functioning scales and global health status denote a better level of functioning (i.e. a better state of the patient), while higher scores on the symptom and single-item scales indicate a higher level of symptoms (i.e. a worse state of the patient).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Locally Advanced Unresectable Pancreatic Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4-weeks stereotactic radiotherapy followed by nivolumab 3 mg/kg every two weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Nivolumab 3 mg/kg intravenously every two weeks untill disease progression or unacceptable toxicity</description>
    <arm_group_label>Arm 1</arm_group_label>
    <other_name>Opdivo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic radiotherapy</intervention_name>
    <description>The prescribed dose will be 32 Gy in four fractions in four weeks (8 Gy per one fraction).</description>
    <arm_group_label>Arm 1</arm_group_label>
    <other_name>Radiation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female patients aged ≥18 years

          2. Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1

          3. Locally advanced, unresectable, histologically confirmed primary adenocarcinoma of
             pancreas with no progression during induction chemotherapy (4 cycles of FOLFIRINOX -
             not a part of trial). Within screening period tumor tissue must be available and sent
             to the central pathological reviewer in order to confirm the diagnosis.

          4. Measurable (one target lesion is sufficient) disease as per RECIST 1.1 criteria

          5. Laboratory values:

               1. Aspartate aminotransferase (AST) ≤ 3x ULN (upper limit of normal)

               2. Alanine transaminase (ALT) ≤ 3x ULN

               3. Total bilirubin ≤ 1.5 x ULN (except subjects with Gilbert syndrome who must have
                  a total bilirubin ≤ 3x ULN)

               4. Creatinine: Serum creatinine ≤ 1.5 ULN or creatinine clearance &gt; 50ml/min (using
                  Cockcroft/Gault formula)

               5. White blood cells ≥ 2000 /ul

               6. Neutrophils ≥ 1500 /ul

               7. Platelets ≥ 100x 103 /ul

               8. Hemoglobin ≥ 9.0 g/l

          6. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test
             (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the
             start of study treatment. WOCBP is defined as any female who has experienced menarche
             and who has not undergone surgical sterilization (hysterectomy or bilateral
             oophorectomy) and who is not postmenopausal. Menopause is defined as 12 months of
             amenorrhea in a woman over age 45 years in the absence of other biological or
             physiological causes. In addition, females under age of 55 years must have serum
             follicle stimulating hormone (FSH) level &gt; 40mIU/ml to confirm menopause.

        Exclusion Criteria:

          1. Other histology then primary pancreatic adenocarcinoma

          2. Resectable disease

          3. Distant metastases

          4. Progressive disease during induction chemotherapy (4 cycles of FOLFIRINOX)

          5. Other previous treatment of the disease except induction chemotherapy (4 cycles of
             FOLFIRINOX)

          6. ECOG performance score of 2 or more

          7. Previous therapy of malignant disease in 5 years and less before inclusion to the
             trial (except skin epithelial tumors)

          8. Previous radiotherapy in abdominal region

          9. Previous immunological treatment (anti-CTLA-4, anti-PD1 or anti-PD-L1)

         10. Active, known or suspected serious autoimmune disease

         11. Major surgery less than 28 days prior to the first dose of study treatment

         12. Treatment of any investigational medicinal product within 4 weeks before this trial
             enrolment

         13. Any positive test for hepatitis B virus or hepatitis C virus indicating acute or
             chronic infection

         14. Known history of testing positive for human immunodeficiency virus (HIV) or known
             acquired immunodeficiency synrome (AIDS)

         15. Prisoners or subjects who are involuntarily incarcerated

         16. Subjects who are compulsorily detained for treatment of either a psychiatric or
             physical (e.g. infectious disease) illness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Milan Vosmik, MD.</last_name>
    <phone>+420 495 832 176</phone>
    <email>milan.vosmik@fnhk.cz</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Johana Krempova, MSc.</last_name>
    <phone>+ 420 601 087 319</phone>
    <email>johana.krempova@fnhk.cz</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Klinika Onkologie a radioterapie, Fakultní nemocnice Hradec Králové</name>
      <address>
        <city>Hradec Králové</city>
        <zip>50005</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Milan Vošmik, MD</last_name>
      <phone>+420 495 832 176</phone>
      <email>milan.vosmik@fnhk.cz</email>
    </contact>
    <investigator>
      <last_name>Milan Vošmik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Onkologická klinika, Fakultní nemocnice Olomouc</name>
      <address>
        <city>Olomouc</city>
        <zip>77900</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bohuslav Melichar, MD</last_name>
      <phone>+420 588 444 292</phone>
      <email>bohuslav.melichar@fnol.cz</email>
    </contact>
    <investigator>
      <last_name>Bohuslav Melichar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Onkologická klinika, Thomayerova nemocnice</name>
      <address>
        <city>Praha</city>
        <zip>14059</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josef Dvořák, MD</last_name>
      <phone>+420 261 083 392</phone>
      <email>josef.dvorak@ftn.cz</email>
    </contact>
    <investigator>
      <last_name>Josef Dvořák, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ústav radiační onkologie, Nemocnice Na Bulovce</name>
      <address>
        <city>Praha</city>
        <zip>18081</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miroslav Pála, MD</last_name>
      <phone>+420 266 084 258</phone>
      <email>miroslav.pala@bulovka.cz</email>
    </contact>
    <investigator>
      <last_name>Miroslav Pála, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 6, 2019</study_first_submitted>
  <study_first_submitted_qc>September 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2019</study_first_posted>
  <last_update_submitted>June 12, 2020</last_update_submitted>
  <last_update_submitted_qc>June 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stereotactic radiotherapy</keyword>
  <keyword>Nivolumab</keyword>
  <keyword>Anti PD-1</keyword>
  <keyword>Pancreatic cancer</keyword>
  <keyword>Pancreatic Adenocarcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

